Course Opens
07/02/2024
Credits
1
Credit Expires
07/02/2025
Patients with triple negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents, which may improve outcomes for patients. However, clinicians lack the ability to implement them into practice appropriately or may be hesitant to use them altogether.
In this Grand Rounds activity, a breast cancer expert will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).
At the conclusion of this activity, learners will be able to better:
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Community oncologists and their interprofessional team of pharmacists, nurses, nurse practitioners (NPs), and physician associates (PAs).
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
Creative Educational Concepts, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.00 contact hours.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity is designated for 1.00 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
OCN®
Care Continuum (Screening, Survivorship/EoL)
Oncology Nursing Practice (Scientific Basis/Profession)
Symptom Management & Palliative Care
Psychosocial Dimensions of Care
AOCNP®/AOCNS®
Cancer Treatment
Side Effect & Symptom Management
Psychosocial Issues
Professional Practice
CPHON®
Cancer Treatment
Side Effect & Symptom Management
Psychosocial Issues
BMTCN®
Professional Performance
CBCN®
Coordination of Care (Breast Health, Screening, Early Detection/Survivorship)
Diagnosis & Staging
Nursing Practice (Symptom Management, EoL Care, Professional)
Psychosocial & Spiritual
Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA.
This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007101-0000-24-004-H01-P).
Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 07/02/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Tolaney reports the following financial relationships:
Consultant/Advisory Board (not leadership): Aadi Biosciences; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer; Blueprint Medicines Corporation; Bristol Myers Squibb Company; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; eFFECTOR; Eisai Inc.; Eli Lilly and Company; Genentech, Inc./Roche; Gilead Sciences, Inc.; Hengrui USA; Incyte; Infinity Therapeutics; Jazz Pharmaceuticals, Inc.; Menarini/Stemline Therapeutics, Inc.; Merck & Co., Inc.; Natera, Inc.; Novartis Pharmaceuticals Corporation; OncXerna Therapeutics, Inc.; Pfizer Inc.; Reveal Genomics; Sanofi; Seattle Genetics; Inc.; Sumitovant Biopharma, Inc.; SystImmune, Inc.; Tango Therapeutics; Umoja Biopharma; Zentalis Pharmaceuticals; and Zymeworks Inc.
Research Support (paid to institution): AstraZeneca; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./Roche; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; Pfizer Inc.; and Seattle Genetics, Inc.
Other financial or material support:
Travel Support: Eli Lilly and Company; Sanofi; Gilead Sciences, Inc.; and Jazz Pharmaceuticals, Inc.
The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Mary Gleason, PhD (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online
(requires free account activation), and participants can print their certificate or statement of
credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.
Call us at 859-260-1717 • info@ceconcepts.com
GRV-030
Call us at 859-260-1717 • info@ceconcepts.com